| 1. |
Yamada A, Noguchi M, Komatsu N, Suekane S, Yutani S, Moriya F, Mine T, Momozono K, Kawano K, Itoh K. Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer. Experimental and therapeutic medicine 2:109-117, 2011. |
| 2. |
Matsumoto K, Noguchi M, Satoh T, Tabata K, Fujita T, Iwamura M, Yamada A, Komatsu N, Baba S, Itoh K. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int (in press) |
| 3. |
Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh Uhi, Kawano K, Azuma K, Uemura H, Okuno K, Matsumoto K, Yanagimoto H, Yamanaka R, Oka M, Todo S, Sasada T, Itoh K. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biology & Therapy 12:1266-79, 2011. |
| 4. |
Noguchi M, Uemura H, Naito S, Akaza H, Yamada A, Itoh K. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate 71:470-9, 2011. |
| 5. |
Komatsu N, Terasaki Y, Moriya F, Suekane S, Noguchi M, Todo S, Itoh K, Shichijo S. Aβ-tubulin 5-derived peptide induces cytotoxic T lymphocytes restricted to the HLA-A24 allele in prostate cancer patients. Experimental and Therapeutic Medicine 1: 833-839, 2010. |
| 6. |
Iseki K, Matsunaga H, Komatsu N, Suekane S, Noguchi M, Itoh K, Yamada A. Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination. Cancer Science 101:2010-2014, 2010. |
| 7. |
Yanagimoto H, Shiomi H, Satoi S, Mine T, Toyokawa H, Yamamoto T, Tani T, Yamada A, A-Hon Kwon, Komatsu N, Itoh K, Noguchi M. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncology Rep 24: 795-801, 2010. |
| 8. |
Yoshida K, Noguchi M, Mine T, Komatsu N, Yutani S, Ueno T, Yanagimoto H, Kawano K, Itoh K and Yamada A. Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: analysis of 500 cases. Oncology Reports 25: 57-62, 2011. |
| 9. |
Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, Itoh K. Overcoming the hurdles of randomized clinical trials of therapeutic cancer vaccine. EJC 46: 1514-1519, 2010. |
| 10. |
Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, Moriya F, Suekane S, Matsuoka K, Komatsu N, Shichijo S, Yamada A, Itoh K. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 59: 1001-1009, 2010. |
| 11. |
Niu Y, Terasaki Y, Komatsu N, Noguchi M, Shichijo S, Itoh K. Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients. Cancer Sci 100: 2167-74, 2009. |
| 12. |
Terasaki Y, Shichijo S, Niu Y, Komatsu N, Noguchi M, Todo S, Itoh K. An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles. Cancer Immunol Immunother 58: 1877-85, 2009. |
| 13. |
Mohamed ER, Naito M, Terasaki Y, Niu Y, Gohara S, Komatsu N, Shichijo S, Itoh K, Noguchi M. Capability of SART3109-118 peptide to induce cytotoxic T-lymphocytes from prostate cancer patients with HLA class ?-A11, -A31, and -A33 alleles. Int J Oncol 34: 529-536, 2009. |
| 14. |
Mohamed ER, Naito M, Terasaki Y, Niu Y, Gohara S, Komatsu N, Shichijo S, Itoh K, Noguchi M. Capability of SART3109-118 peptide to induce cytotoxic T-lymphocytes from prostate cancer patients with HLA class ?-A11, -A31, and -A33 alleles. Int J Oncol 34: 529-536, 2009. |
| 15. |
Naito M, Itoh K, Komatsu N, Yamashita Y, Shirakusa T, Yamada A, Moriya F, Ayatuka H, Mohamed ES, Matsuoka K, Noguchi M. Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients. Prostate 68: 1753-1762, 2008. |
| 16. |
Noguchi M, Kakuma T, Suekane S, Nakashima O, Mohamed ER, Matsuoka K: A randomized clinical trial of suspension technique for improving early recovery of urinary continence after radical retropubic prostatectomy. BJU Int 102: 958-963, 2008. |
| 17. |
Noguchi M, Kakuma T, Tomiyasu K, Yamada A, Itoh K, Konishi F, Kumamoto S, Shimizu K, Kondo R, Matsuoka K. Randomized clinical trial of an ethanol extract of Ganlderma lucidum in men with lower urinary tract symptoms. Asian J Androl 10: 777-785, 2008. |
| 18. |
Naito M, Yoshihiro K, Ishihara Y, Noguchi M, Yamashita Y, Shirakusa T, Yamada A, Itoh K, Harada M. Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles. Br J Cancer 97: 1648-1654, 2007. |
| 19. |
Noguchi M, Kakuma T, Tomiyashu K, Kurita Y, Kukihara H, Konishi F, Kumamoto S, Shimizu K, Kondo R., Matsuoka K. Effect of an extract of Ganoderma lucidum in men with lower urinary tract symptoms: a double-blind, placebo-controlled randomized and dose-ranging study. Asian J Androl 10: 651-658, 2008. |
| 20. |
Suekane S, Nishitani M, Noguchi M, Komohara Y, Kokubu T, Naitoh M, Honma S, Yamada A, Itoh K, Matuoka K, Kanayama H. A phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer Sci 98: 1965-1968 (2007) |
| 21. |
Komohara Y, Harada M, Ishihara Y, Suekane S, Noguchi M, Yamada A, Matsuoka K, Itoh K. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. Oncology Reports 18: 1463-1468, 2007. |
| 22. |
Itoh Y, Komohara Y, Komatsu N, Minami T, Saito K, Noguchi M, Itoh K, Harada M. New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients. Oncology Reports 18: 1231-1237, 2007. |
| 23. |
Homma S, Komohara Y, Harada M, Saya H, Todo S, Itoh K, Noguchi M. Differential levels of human leukocyte antigen-class I, multidrug-resistance 1, and androgen receptor expressions in untreated prostate cancer cells: the robustness of prostate cancer. Oncology Reports 18: 343-346, 2007. |
| 24. |
Suekane S, Noguchi M, Nakashima O, Yamada S, Kojiro M, Matsuoka K.Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy. Int J Urol 14: 713-718, 2007. |
| 25. |
Noguchi M, Yao A, Harada M, Nakashima O, Komohara Y, Yamada S, Itoh K, Matsuoka K. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate 67: 933-942, 2007. |
| 26. |
Noguchi M, Mine T, Yamada A, Obata Y, Yoshida K, Mizoguchi J, Harada M, Suekane S, Itoh K, Matsuoka K. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: An analysis of prognostic factors in the treatment. Oncol Res 16: 341-349, 2007. |
| 27. |
Komohara Y, Suekane S, Noguchi M, Matsuoka K, Yamada A, Itoh K. Expression of APOBEC3G in kidney cells. Tissue antigens, 69: 95-98, 2007. |
| 28. |
Matsueda S, Takedatsu H, Sasada Y, Azuma K, Ishihara Y, Komohara Y, Noguchi M, Shichijo S, Itoh K, Harada M. New Peptide Vaccine Candidates for Epithelial Cancer Patients with HLA-A3 Supertype Alleles. J Immunother, 30: 274-281, 2007. |
| 29. |
Komohara Y, Harada M, Arima Y, Suekane S, Noguchi M, Yamada A, Itoh K, Matsuoka K. Identification of target antigens in specific immunotherapy for renal cell carcinoma. J Urol 177: 1157-1162, 2007. |
| 30. |
Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K, Harada M. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunol Immun 56: 689-698, 2007. |
